Interaction between sympathetic nervous system and renin angiotensin system on MMPs expression in juvenile rat aorta

General Physiology and Biophysics

Volumn 30, Issue 3, 2011, Pages 271-277

  Dab, Houcine ^a,b   Hachani, Rafik ^a   Hodroj, Wassim ^b   Sakly, Mohsen ^a   Bricca, Giampiero ^b   Kacem, Kamel ^a  

^a Struggle and Prevention   (Tunisia)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Angiotensin II; Aorta; AT1R antagonist; MMP 2; MMP 9; Sympathectomy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; GELATINASE A; GELATINASE B; GUANETHIDINE; LOSARTAN; MESSENGER RNA;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOBLOTTING; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPATHECTOMY; ZYMOGRAPHY;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; RATS; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYMPATHETIC NERVOUS SYSTEM;

RATTUS;

EID: 80054119747     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/gpb_2011_03_271     Document Type: Article

References (29)

1. Balt J. C., Mathy M. J., Nap A., Pfaffendorf M., van Zwieten P. A. (2001): Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J. Cardiovasc. Pharmacol. 1, 141-148 doi:10.1097/00005344-200107000-00015 (Pubitemid 32634998)
2. Browatzki M. D., Pfeiffer C. A., Gehrke S. G., Schmidt J., Kranzhofer A., Katus H. A. Kranzhofer R. (2005): Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J. Vasc. Res. 5, 415-423 doi:10.1159/000087451 (Pubitemid 41368960)
3. Cipollone F., Fazia M., Iezzi A., Pini B., Cuccurullo C., Zucchelli M., de Cesare D., Ucchino S., Spigonardo F., De Luca M., Muraro R., Bei R., Bucci M., Cuccurullo F., Mezzetti A. (2004): Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109, 1482-1488 doi:10.1161/01.CIR.0000121735.52471.AC (Pubitemid 38420175)
4. Coker M. L., Jolly J. R., Joffs C., Etoh T., Holder J. R., Bond B. R., Spinale F. G. (2001): Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am. J. Physiol. Heart. Circ. Physiol. 2, H543-551
5. Dab H., Hachani R., Hodroj W., Sakly M., Bricca G., Kacem K. (2009): Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle. Auton. Neurosci. 2, 27-32 doi:10.1016/j.autneu.2009.04.002
6. Dendorfer A., Raasch W., Tempel K., Dominiak P. (1998): Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic. Res. Cardiol. 93, 24-29 doi:10.1007/s003950050202 (Pubitemid 28498126)
7. Dwyer K. W., Provenzano P. P., Muir P., Valhmu W. B., Vanderby R. Jr. (2004): Blockade of the sympathetic nervous system degrades ligament in a rat MCL model. J. Appl. Physiol. 96, 711-718 doi:10.1152/japplphysiol.00307.2003 (Pubitemid 38140177)
8. Eagleton M. J., Ballard N., Lynch E., Srivastava S. D., Upchurch G. R. Jr., Stanley J. C. (2006): Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during Angiotensin II induced aneurysm formation. J. Surg. Res. 2, 345-351 doi:10.1016/j.jss.2006.03.026 (Pubitemid 44414882)
9. Galis Z. S., Khatri J. J. (2002): Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 3, 251-262 (Pubitemid 34633925)
10. Gironacci M. M., Adler-Graschinsky E., Peña C., Enero M. A. (1994): Effects of angiotensin II and angiotensin-(1-7) on the release of [3H]norepinephrine from rat atria. Hypertension 24, 457-460 (Pubitemid 24296467)
11. Guo R. W., Yang L. X., Wang H., Liu B., Wang L. (2008): Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB- dependent pathway in vascular smooth muscle cells. Regul. Pept. 3, 37-44 doi:10.1016/j.regpep.2007.12.005
12. Heath J. W., Burnstock G. (1977): Selectivity of neuronal degeneration produced by chronic guanethidine treatment. J. Neurocytol. 4, 397-405 doi:10.1007/BF01178225 (Pubitemid 8136335)
13. Johnson E. M. Jr., O'Brien F., Werbitt R. (1976): Modification and characterization of the permanent sympathectomy produced by the administration of guanethidine to newborn rats. Eur. J. Pharmacol. 1, 45-54 doi:10.1016/0014-2999(76)90006-6
14. Lindsey M., Wedin K., Brown M. D., Keller C., Evans A. J., Smolen J., Burns A. R., Rossen R. D., Michael L., Entman M. (2001): Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 17, 2181-2187 (Pubitemid 32458328)
15. Luchtefeld M., Grote K., Grothusen C., Bley S., Bandlow N., Selle T., Strüber M., Haverich A., Bavendiek U., Drexler H., Schieffer B. (2005): Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem. Biophys. Res. Commun. 1, 183-188 doi:10.1016/j.bbrc.2004.12.152 (Pubitemid 40164653)
16. Messerli F. H. (2004): TIMPs, MMPs and cardiovascular disease. Eur. Heart. J. 17, 1475-1476 doi:10.1016/j.ehj.2004.07.015
17. Miner E. C., Miller W. L. (2006): A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo. Clin. Proc. 1, 71-76 doi:10.4065/81.1.71 (Pubitemid 43054320)
18. Nagase H., Brew K. (2003): Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem. Soc. Symp. 70, 201-212 (Pubitemid 38497226)
19. Qin Z. (2008): Newly developed angiotensin II-infused experimental models in vascular biology. Regul. Pept. 150, 1-6 doi:10.1016/j.regpep.2008.05.002
20. Raasch W., Dominiak P., Ziegler A., Dendorfer A. (2004): Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension 3, 346-3451 doi:10.1161/01.HYP.0000138406. 13413.0e
21. Rocha F. L., Carmo E. C., Roque F. R., Hashimoto N. Y., Rossoni L. V., Frimm C., Anéas I., Negrão C. E., Krieger J. E., Oliveira E. M. (2007): Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. Am. J. Physiol. Heart. Circ. Physiol. 6, H3575-3583 doi:10.1152/ajpheart.01251.2006 (Pubitemid 350230902)
22. Sukhova G. K., Schönbeck U., Rabkin E., Schoen F. J., Poole A. R., Billinghurst R. C., Libby P. (1999): Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99, 2503-2509 (Pubitemid 29228279)
23. Supowit S. C., Ethridge R. T., Zhao H., Katki K. A., Dipette D. J. (2005): Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am. J. Physiol. Heart. Circ. Physiol. 3, H1169-1175 doi:10.1152/ajpheart.00973.2004 (Pubitemid 41208960)
24. Timmermans P. B., Smith R. D. (1994): Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart. J. 15, 79-87
25. Villanueva I., Piñón M., Quevedo-Corona L., Martínez-Olivares R., Racotta R. (2003): Epinephrine and dopamine colocalization with norepinephrine in various peripheral tissues: guanethidine effects. Life Sci. 13, 1645-1653 doi:10.1016/S0024-3205(03)00491-0 (Pubitemid 36859870)
26. Wang M., Zhang J., Spinetti G., Jiang L. Q., Monticone R., Zhao D., Cheng L., Krawczyk M., Talan M., Pintus G., Lakatta E. G. (2005): Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am. J. Pathol. 167, 1429-1442 doi:10.1016/S0002-9440(10)61229-1 (Pubitemid 41541428)
27. Wu T. C., Chen Y. H., Leu H. B., Chen Y. L., Lin F. Y., Lin S. J., Chen J. W. (2007): Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic. Biol. Med. 11, 1508-1522 doi:10.1016/j.freeradbiomed.2007.08.010
28. Xie Z., Singh M., Singh K. (2004): Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J. Biol. Chem. 279, 39513-39519 doi:10.1074/jbc.M405844200 (Pubitemid 39258218)
29. Yang E. V., Sood A. K., Chen M., Li Y., Eubank T. D., Marsh C. B., Jewell S., Flavahan N. A., Morrison C., Yeh P. E., Lemeshow S., Glaser R. (2006): Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 21, 10357-10364 doi:10.1158/0008-5472.CAN-06-2496 (Pubitemid 44799755)